ClinicalTrials.gg
Not yet recruitingNCT06946004NBO-ONCOUpdated Apr 27, 2025

Normobaric Oxygen Therapy in Colorectal Cancer Patients

An interventional study of Normobaric oxygen therapy and Normobaric oxygen therapy in Colorectal Cancer (CRC), sponsored by 4th Military Clinical Hospital with Polyclinic, Poland. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by 4th Military Clinical Hospital with Polyclinic, Poland · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Colorectal Neoplasms with a site in Poland — 20 open to participants now, 34 under way, 14 of them phase 3. Colorectal Neoplasms · Poland.

Planned enrollment
68th of 103
254 · median 473
Started
2025
with 4 others
No phase
21 of 118
4 open now
Primary completion
2027-11
later than 17 of 33 live
Registered
109th of 118
by date

Among the 118 studies in Colorectal Neoplasms with a site in Poland, this one is the 68th largest by planned enrollment of the 103 interventional ones that give a count, is one of 5 that started in 2025, is one of 21 with no phase, reaches primary completion later than 17 of the 33 other live ones, and was the 109th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

20 of the 118 studies in Colorectal Neoplasms with a site in Poland are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Colorectal Neoplasms with a site in Poland, or all of them as a file.
02

Study summary

Colorectal cancer (CRC) patients undergoing chemotherapy often experience anemia, oxidative stress, and immune suppression, significantly impacting their quality of life and treatment outcomes. Normobaric oxygen (NBO) therapy, which delivers oxygen at atmospheric pressure with elevated oxygen concentration, has shown a potential to enhance erythropoiesis, reduce oxidative stress, and modulate immune function. However, its efficacy in CRC patients remains underexplored. This study aims to evaluate the effects of NBO exposures on (1) supporting erythropoiesis by measuring erythropoietin (EPO) levels and hypoxia-inducible factors (HIF-1α), (2) reducing oxidative stress and improving stress and emotional well-being, and (3) modulating immune function by assessing cytokine profiles. Secondary objectives include assessing the impact of NBO on patient-reported outcome measures (PROMs) such as stress, anxiety, depression, and quality of life. This is a prospective, randomized, double-blind, placebo-controlled clinical trial. A total of 254 CRC patients undergoing chemotherapy will be randomized 1:1 to receive either active NBO therapy (n=127) or placebo NBO therapy (n=127). The intervention consists of 10 NBO sessions over five weeks. Primary outcomes include biomarkers of erythropoiesis, oxidative stress, and immune response. Secondary outcomes assess quality of life and psychological well-being. Data will be collected at baseline, mid-intervention, post-intervention, and during two follow-up visits (3- and 6-months post-intervention). The study hypothesizes that NBO therapy will improve erythropoiesis, reduce oxidative stress, and enhance immune function in CRC patients, leading to improved quality of life and clinical outcomes. Findings from this trial may establish NBO as a novel supportive therapy for CRC patients undergoing chemotherapy.

Read the detailed description

The intervention will involve NBO as a supportive treatment for CRC patients undergoing chemotherapy. The NBO protocol consists of regular sessions in a normobaric chamber where patients are exposed to controlled oxygen levels aimed at reducing ox-idative stress, supporting erythropoiesis, and modulating immune function. Patients in the CRC group will undergo 10 NBO sessions across five weeks, with two sessions weekly.

Patient's exposure to NBO conditions in group 1 (aNBO) including: oxygen levels of 32-40% (compared to about 21% in the atmosphere), pressure maintained at 1,500 hPa (about 1,000 hPa outside), carbon dioxide levels between 0.7-1.9% (compared to 0.03% in the atmosphere, and hydrogen levels between 0.5-1% (which is 10 to 20 thousand times higher than in the atmosphere). Exposure time in the NBO chamber will be the standard 2 hours with an additional 20 minutes for preparation and adaptation and 10 minutes for the finalization and decompression period.

Patients' exposure to atmospheric conditions in the same NBO chamber (without normobaric conditions to provide sham-placebo intervention) in group 2 (pNBO): oxygen levels about 21%, pressure maintained at about 1,000 hPa, carbon dioxide levels about o 0.03%, and hydrogen levels about 0.00005% (0.5 parts per million, like in the atmos-phere). The primary comparator in this study is the placebo NBO group (CRC patients; n=127) for CRC patients, which serves to differentiate the specific effects of active NBO from the natural course of treatment without enhanced oxygen exposure.

The patient assessment scheme contains six visits from V0 to V5 with subsequent analytical packages with detailed explanation in 2.8. section. The patient assessment schedule consists of six visits, from V0 to V5, each including specific evaluations and interventions. The study begins with V0 (prequalification/screening), where patient consent is obtained, medical history is collected, and baseline data are recorded. V1 (randomization and pre-test visit) involves the initial assessments, including anemia, stress, immune, genetic markers, and patient-reported outcomes (PROMs). Following this, the first phase of the NBO intervention (sessions 1-5) takes place over five weeks. At V2 (midpoint evaluation), the same set of assessments is repeated to track progress, followed by the second phase of the NBO intervention (sessions 6-10) conducted over the next five weeks. V3 (finalization and post-test visit) marks the completion of the intervention, with a final round of primary and secondary outcome assessments. The study then proceeds with two follow-up visits: V4 (3-months post-NBO) and V5 (6-months post-NBO), where anemia, stress, immune, genetic markers, and PROMs are reassessed to evaluate the long-term effects of the intervention.

03

Conditions studied

  • Colorectal Cancer (CRC)

Keywords

  • colorectal cancer
  • normobaric oxygen therapy
  • chemotherapy-induced anemia
  • oxidative stress
  • immune modulation
  • erythropoiesis
  • supportive cancer care
  • adverse effects
  • stress
  • anxiety
  • depression
  • psychological well-being
  • quality of life
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age between 18 and 80 years (participants must be adults)
  • diagnosed with CRC (stage II-IV, scheduled for standard chemotherapy (for study and control groups)
  • baseline levels above 10 g/dL
  • no concurrent hematologic
  • (ECOG) performance status of 0-2 (ensuring participants are ambulatory and capable of self-care)
  • of at least 12 months (participants are expected to survive the duration of the study)
  • ability and willingness to comply with all study procedures and schedules (including NBO therapy sessions and follow-up visits)
  • adequate organ function as determined by laboratory tests (liver function tests - , AST), renal function tests (serum creatinine, )
  • women of must have a negative pregnancy test prior to enrollment and agree to use effective during the study (to ensure safety for potential pregnancies)
  • written obtained prior to any study-related procedures (participants must understand and agree to all aspects of the study).

Exclusion criteria

Exclusion Criteria:

  • age under 18 years or over 80 years
  • severe cardiovascular or respiratory conditions (e.g., unstable angina, recent myocardial infarction, advanced )
  • severe anemia ( \<10 g/dL) or any hemolytic disorder that could confound study outcomes
  • uncontrolled diabetes mellitus (e.g., >8.0% or poor glycemic control requiring frequent hospitalizations)
  • pregnancy or breastfeeding
  • severe infection or status unrelated to cancer (e.g., advanced infection)
  • current psychiatric or neurological disorders that could interfere with study participation
  • participation in other therapies within the last 30 days; (9) lack of written for study participation
  • or inflammatory conditions (e.g., lupus, rheumatoid arthritis on immunosuppressive therapy) that significantly alter immune responses
  • presence of any for NBO therapy (e.g., active bleeding, acute infections, inflammation of the optic nerve, epilepsy or seizures, uncontrolled diabetes as noted above, pneumothorax, emphysema, electronic implants).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
254 participants (estimated)

Study arms

  • Experimental
    active NBO therapy (n=127)

    Patient's exposure to NBO conditions in group 1 (aNBO)

    Device: Normobaric oxygen therapy

  • Placebo comparator
    placebo NBO therapy (n=127)

    Patients' exposure to atmospheric conditions in the same NBO chamber without normobaric conditions in group 2 (pNBO)

    Device: Normobaric oxygen therapy

Interventions

  • DeviceNormobaric oxygen therapy

    Patient's exposure to NBO conditions in group 1 (aNBO) including: oxygen levels of 32-40% (compared to about 21% in the atmosphere), pressure maintained at 1,500 hPa (about 1,000 hPa outside), carbon dioxide levels between 0.7-1.9% (compared to 0.03% in the atmosphere, and hydrogen levels between 0.5-1% (which is 10 to 20 thousand times higher than in the atmosphere). Exposure time in the NBO chamber will be the standard 2 hours with an additional 20 minutes for preparation and adaptation and 10 minutes for finalization and the decompression period.

  • DeviceNormobaric oxygen therapy

    Patients' exposure to atmospheric conditions in the same NBO chamber (without normobaric conditions to provide placebo intervention as the study comparator) in group 2 (pNBO): oxygen levels about 21%, pressure maintained at about 1,000 hPa, carbon dioxide levels about o 0.03%, and hydrogen levels about 0.00005% (0.5 parts per million, like in the atmos-phere).

06

What researchers measure

Primary outcomes

  1. Erythropoietin (EPO) concentration

    Erythropoietin (EPO) concentration \[mU/mL\] will be measured using a quantitative immunoassay (ELISA) at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  2. Hypoxia-inducible factor-1α (HIF-1α)

    Hypoxia-inducible factor-1α (HIF-1α) \[ng/mL\] will be measured using a quantitative immunoassay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  3. Reticulocyte count

    Reticulocyte count \[% of total red blood cells\] will be measured using an automated hematology analyzer at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  4. Red blood cell (RBC)

    Red blood cell (RBC) count \[10¹² cells/L\] will be measured using 5-part differential blood morphology on an automated hematology analyzer at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  5. Hemoglobin concentration (HGB)

    Hemoglobin concentration (HGB) \[g/dL\] will be measured using an automated hematology analyzer at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  6. Hematocrit

    Hematocrit \[%\] will be measured using an automated hematology analyzer at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  7. Serum creatinine

    Serum creatinine \[µmol/L\] will be measured using an enzymatic assay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  8. Estimated glomerular filtration rate (eGFR)

    Estimated glomerular filtration rate (eGFR) \[mL/min/1.73 m²\] will be calculated using the CKD-EPI equation at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  9. Alanine aminotransferase (ALT)

    Alanine aminotransferase (ALT) \[IU/L\] will be measured using an enzymatic assay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  10. Aspartate aminotransferase (AST)

    Aspartate aminotransferase (AST) \[IU/L\] will be measured using an enzymatic assay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  11. Fasting glucose

    Fasting glucose \[mmol/L\] will be measured using a hexokinase assay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  12. Fasting insulin

    Fasting insulin \[µU/mL\] will be measured using an immunoassay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  13. Lipid profile

    Lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) \[mmol/L\] will be measured using enzymatic/colorimetric assays at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  14. Iron metabolism (serum iron, total iron-binding capacity [TIBC]

    Iron metabolism (serum iron, total iron-binding capacity \[TIBC\] \[µmol/L\], ferritin \[ng/mL\], vitamin B₁₂ \[pg/mL\]) will be measured using immunoassays at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  15. Serum albumin

    Serum albumin \[g/L\] will be measured using a bromcresol green assay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  16. C-reactive protein (CRP)

    C-reactive protein (CRP) \[mg/L\] will be measured using a high-sensitivity immunoturbidimetric assay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  17. Reactive oxygen species (ROS) level

    Reactive oxygen species (ROS) level \[relative fluorescence units\] will be measured using a chemiluminescence assay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up]

  18. Serum cortisol

    Serum cortisol \[µg/dL\] will be measured using a high-sensitivity immunoassay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  19. Gamma-aminobutyric acid (GABA)

    Gamma-aminobutyric acid (GABA) \[µmol/L\] will be measured using an enzyme-linked immunosorbent assay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  20. Dopamine

    Dopamine \[ng/mL\] will be measured using a competitive immunoassay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  21. Serotonin

    Serotonin \[ng/mL\] will be measured using a competitive immunoassay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  22. Fibrinogen

    Fibrinogen \[g/L\] will be measured using the Clauss clotting assay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  23. Glycated hemoglobin (HbA₁c)

    Glycated hemoglobin (HbA₁c) \[%\] will be measured using high-performance liquid chromatography at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  24. Dehydroepiandrosterone-sulfate (DHEA-S)

    Dehydroepiandrosterone-sulfate (DHEA-S) \[µg/dL\] will be measured using an immunoassay at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  25. Systolic blood pressure (SBP)

    Systolic blood pressure (SBP) \[mmHg\] will be measured using an automated sphygmomanometer at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  26. Diastolic blood pressure (DBP)

    Diastolic blood pressure (DBP) \[mmHg\] will be measured using an automated sphygmomanometer at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  27. Heart rate (HR)

    Heart rate (HR) \[beats per minute\] will be measured using an automated sphygmomanometer at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  28. Body mass index (BMI)

    Body mass index (BMI) \[kg/m²\] will be calculated from measured weight and height at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  29. Body surface area (BSA)

    Body surface area (BSA) \[m²\] will be calculated using the Mosteller formula from measured weight and height at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  30. Waist-to-hip ratio (WHR)

    Waist-to-hip ratio (WHR) \[ratio\] will be calculated from measured waist and hip circumferences at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  31. Tumor necrosis factor-α (TNF-α)

    Tumor necrosis factor-α (TNF-α) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  32. Interleukin-1β (IL-1β)

    Interleukin-1β (IL-1β) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  33. Interleukin-6 (IL-6)

    Interleukin-6 (IL-6) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  34. Interleukin-10 (IL-10)

    Interleukin-10 (IL-10) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  35. Monocyte chemoattractant protein-1 (MCP-1/CCL2)

    Monocyte chemoattractant protein-1 (MCP-1/CCL2) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  36. Macrophage inflammatory protein-1α (MIP-1α/CCL3)

    Macrophage inflammatory protein-1α (MIP-1α/CCL3) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  37. Macrophage inflammatory protein-1β (MIP-1β/CCL4)

    Macrophage inflammatory protein-1β (MIP-1β/CCL4) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  38. Vascular endothelial growth factor A (VEGF-A)

    Vascular endothelial growth factor A (VEGF-A) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  39. Platelet-derived growth factor-BB (PDGF-BB)

    Platelet-derived growth factor-BB (PDGF-BB) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

Secondary outcomes

  1. Stress level (self-assessment)

    The Perceived Stress Questionnaire (PSQ-30) is a 30-item self-report instrument designed to assess perceived stress over the previous month. Each item is rated on a 4-point Likert scale (1 = "almost never" to 4 = "usually"), yielding a raw score that can range from 30 (minimum) to 120 (maximum). Higher raw scores indicate greater perceived stress (worse outcome). The PSQ-30 will be administered at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  2. Anxiety and depression levels (self-assessment)

    The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-report questionnaire comprising two subscales: HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D). Each subscale contains 7 items scored on a 4-point Likert scale (0 = "not at all" to 3 = "very often"), yielding subscale scores from 0 (minimum) to 21 (maximum). Higher scores indicate greater symptom severity (worse outcome). The HADS total score (sum of HADS-A and HADS-D) ranges from 0 to 42. The HADS will be administered at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

  3. Quality of live level (self-assessment)

    EuroQol Five-Dimension Five-Level questionnaire (EQ-5D-5L) index score \[-0.59 to 1.00; higher = better health\] will be derived from five domains-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-each rated on a 5-point scale (1 = no problems to 5 = extreme problems). Health states will be converted to a single index value using the Polish EQ-5D-5L value set. The EQ-5D-5L will be administered at V1, V2, V3, V4, and V5.

    Time frame: From enrollment to the end of 6th month follow-up

07

Study locations

1 site
  • 4th Military Clinical Hospital
    Wroclaw, 50-981, Poland
    • Beata Jankowska-Polańska Prof., PhD · Contactdyrektor@cwbk.4wsk.pl · +48 71 727 41
    • Jacek Polański Dr, PhD · Principal investigator
    • Edyta Pawlak Prof., PhD · Sub investigator
    • Beata Freier MD, PhD · Sub investigator
08

References and documents

Publications

  • Lin CH, Su WH, Chen YC, Feng PH, Shen WC, Ong JR, Wu MY, Wong CS. Treatment with normobaric or hyperbaric oxygen and its effect on neuropsychometric dysfunction after carbon monoxide poisoning: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Sep;97(39):e12456. doi: 10.1097/MD.0000000000012456. PubMed 30278526 ↗
  • Bloch Y, Belmaker RH, Shvartzman P, Romem P, Bolotin A, Bersudsky Y, Azab AN. Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial. Sci Rep. 2021 Sep 23;11(1):18911. doi: 10.1038/s41598-021-98245-9. PubMed 34556722 ↗
  • Kujawski S, Slomko J, Morten KJ, Murovska M, Buszko K, Newton JL, Zalewski P. Autonomic and Cognitive Function Response to Normobaric Hyperoxia Exposure in Healthy Subjects. Preliminary Study. Medicina (Kaunas). 2020 Apr 10;56(4):172. doi: 10.3390/medicina56040172. PubMed 32290164 ↗
  • De Bels D, Theunissen S, Devriendt J, Germonpre P, Lafere P, Valsamis J, Snoeck T, Meeus P, Balestra C. The 'normobaric oxygen paradox': does it increase haemoglobin? Diving Hyperb Med. 2012 Jun;42(2):67-71. PubMed 22828812 ↗
  • Saleh EAM, Al-Dolaimy F, Qasim Almajidi Y, Baymakov S, Kader M MA, Ullah MI, Abbas AHR, Khlewee IH, Bisht YS, Alsaalamy AH. Oxidative stress affects the beginning of the growth of cancer cells through a variety of routes. Pathol Res Pract. 2023 Sep;249:154664. doi: 10.1016/j.prp.2023.154664. Epub 2023 Jul 1. PubMed 37573621 ↗
  • Noman MZ, Hasmim M, Lequeux A, Xiao M, Duhem C, Chouaib S, Berchem G, Janji B. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Cells. 2019 Sep 14;8(9):1083. doi: 10.3390/cells8091083. PubMed 31540045 ↗
  • Bozzini C, Busti F, Marchi G, Vianello A, Cerchione C, Martinelli G, Girelli D. Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches. Front Oncol. 2024 Apr 2;14:1380358. doi: 10.3389/fonc.2024.1380358. eCollection 2024. PubMed 38628673 ↗
  • Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012 Aug;13(8):790-801. doi: 10.1016/S1470-2045(12)70211-5. Epub 2012 Jun 1. PubMed 22658655 ↗
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Nov 2027, 24 months later.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 24 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 27, 2025
StartEst.
Nov 1, 2025
Primary completionEst.
Nov 1, 2027
CompletionEst.
Nov 1, 2028
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06946004
Lead sponsor
4th Military Clinical Hospital with Polyclinic, Poland
Collaborators
Wroclaw Medical University (Poland), Wroclaw University of Science and Technology (Poland), Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (Poland), WSB Merito University in Opole (Poland), Academy of Applied Sciences in Nowy Sacz (Poland)
Responsible party
Sponsor
First posted
Apr 27, 2025
Start date
Nov 1, 2025 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Apr 27, 2025

Study contacts

Beata Jankowska-Polańska Prof., PhD
Contact
dyrektor@cwbk.4wsk.pl
+48 71 727 41 52

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion